STELLAR-303:MSS大腸がんにおける免疫療法の壁を破る
Hideaki Bando1, Takayuki Yoshino1
1Department of Gastroenterology & Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan; Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.
Abstract:
The phase 3 STELLAR-303 trial1 demonstrated a significant overall survival benefit of zanzalintinib plus atezolizumab over regorafenib in refractory microsatellite-stable (MSS) metastatic colorectal cancer, marking the first phase 3 success of an immunotherapy-based regimen in this population. These results may reshape treatment paradigms and renew interest in biomarker-guided immunotherapy for MSS disease.
関連する概念動画
Tumor Immunotherapy
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...


